ALRN Aileron Therapeutics
- 3.8200
- +0.1500+4.09%
Aileron Therapeutics News
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
Aileron Therapeutics Closes Direct Offering of Shares, Warrants
Aileron Therapeutics (ALRN) said late Friday it closed an underwritten registered direct offering of about 4.3 million shares and warrants to buy the same number of shares. Each share and warrant were
Press Release: Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential fo
Aileron Therapeutics(ALRN.US) 10% Shareholder Sells US$139.1K in Common Stock
$Aileron Therapeutics(ALRN.US)$ 10% Shareholder UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO sold 31,151 shares of common stock on Apr 29, 30, May 1, 2024 at an average price of $4.465 for a
Aileron Therapeutics Prices 4,273,505 Offering Of Shares And Accompanying Warrants At Combined Offering Price Of $4.68
Aileron Therapeutics Prices 4,273,505 Offering Of Shares And Accompanying Warrants At Combined Offering Price Of $4.68
Aileron Therapeutics Announces Positive Data From Its Early Stage Pulmonary Fibrosis Treatment Trial
Press Release: Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million Includes initial funding of approximately
Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a
Form 144 | Aileron Therapeutics(ALRN.US) 10% Stockholder Proposes to Sell 3.62 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 29, $Aileron Therapeutics(ALRN.US)$ 10% Stockholder UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO intends to sell 723.98K shares of its common stock on Apr 29, with
CGC, GENE and HOLO Among Mid-day Movers
Aileron Therapeutics Filed U.S. Patent Application #20240124518: Methods For Preparing Purified Polypeptide Compositions
Aileron Therapeutics Filed U.S. Patent Application #20240124518: Methods For Preparing Purified Polypeptide Compositions
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results.The company reported quarterly adjusted earnings of 75 cents per sh
Veru, EyePoint Pharmaceuticals, SINTX Technologies Among Healthcare Movers
Ladenburg Thalmann: Maintaining the Aileron Therapeutics (ALRN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $19.00.
Ladenburg Thalmann: Maintaining the Aileron Therapeutics (ALRN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $19.00.
Ladenburg Thalmann Maintains Buy on Aileron Therapeutics, Raises Price Target to $19
Ladenburg Thalmann analyst Aydin Huseynov maintains Aileron Therapeutics with a Buy and raises the price target from $9 to $19.
Aileron Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/18/2024 280.76% Ladenburg Thalmann $9 → $19 Maintains Buy 12/01/2023 80.36% Ladenburg Thalmann → $9 Upg
Aileron Therapeutics (ALRN.US): The 2023 Q4 earnings report achieved revenue of $0, previous value of $0; earnings per share were -1.54 dollars, previous value of -1.02 dollars.
Aileron Therapeutics (ALRN.US): The 2023 Q4 earnings report achieved revenue of $0, previous value of $0; earnings per share were -1.54 dollars, previous value of -1.02 dollars.
Aileron Therapeutics GAAP EPS of -$1.54 Misses by $1.37
Aileron Therapeutics Q4 EPS $(1.54) Down From $(1.00) YoY; Cash Runway Expected To Fund Operations And Key Milestones Into Q4 Of 2024
Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(1.54) per share versus losses of $(1.00) per share from the same period last year.
Aileron Therapeutics 4Q Loss $7.34M >ALRN
Aileron Therapeutics 4Q Loss $7.34M >ALRN
Analysis
Price Target
No Data
